Ipamorelin

ID: ipamorelin

Aliases: NNC 26-0161, IPAMORELIN

Type: compound

Route/form: subcutaneous injection

Status: research

Evidence level: early human

Best data tier: early human

Support scope: human, non-human/mechanistic

Source types: early_human, preclinical

Linked sources: 2

Broad outcomes: Fat loss / metabolic health, Hormones / fertility / sexual health, Muscle growth / performance / recovery, PEDs / AAS / thermogenics

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• GHSR agonist
• GH secretagogue

Optimization domains

• growth hormone
• body composition

Research basis

• Ipamorelin has human volunteer PK/PD data and is mechanistically a selective growth hormone secretagogue, which explains its use as a cleaner GHRP comparator.
• Compared with older GHRPs, the rationale is a GH pulse with less prolactin/cortisol signal, though that is still primarily a pharmacology claim.
• Optimization relevance is strongest as a GH-axis probe or adjunct concept, not as proven standalone body recomposition.

Limits, risks, and missing evidence

• Human endpoint data for muscle gain, fat loss, connective-tissue repair, or anti-aging are not robust.
• Secretagogue selectivity does not remove GH/IGF-1 adverse-effect concerns such as edema, glucose effects, sleep apnea, and endocrine feedback.
• Vendor stack claims usually exceed the available human outcomes.

Risk flags

• investigational
• endocrine axis
• gh igf1 axis
• limited outcome data

Linked papers, labels, and reviews

1. Ipamorelin, the first selective growth hormone secretagogue
   preclinical / pubmed_ipamorelin_1998
   Discovery and pharmacology paper.
2. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers
   early_human / pubmed_ipamorelin_human_pkpd
   Human volunteer PK/PD modeling.